New INH-pyrazole analogs: Design, synthesis and evaluation of antitubercular and antibacterial activity

dc.contributor.authorNayak, N.
dc.contributor.authorRamprasad, J.
dc.contributor.authorUdayakumar, U.
dc.date.accessioned2026-02-05T09:33:31Z
dc.date.issued2015
dc.description.abstractWith the aim of developing promising antitubercular and antibacterial leads, we have designed and synthesized a new series of isonicotinohydrazide based pyrazole derivatives (5a-r). All new derivatives (4a-b and 5a-r) were screened for in vitro antimycobacterial activity against Mycobacterium tuberculosis H<inf>37</inf>Rv (MTB) strain. Four compounds 5j, 5k, 5l and 4b emerged as promising antitubercular agents with MIC of ?4.9 ?M which is much lower than the MIC of the first line antitubercular drug, ethambutol. The 3-chlorophenyl substituent at position-3 of the pyrazole ring enhanced the antiTB activity of the molecules. Three derivatives 5b, 5k and 4b exhibited promising antibacterial activity against the tested bacterial strains. The active molecules were nontoxic to normal Vero cells and showed high selectivity index (>160). The structure and antitubercular activity relationship was further supported by in silico molecular docking study of the active compounds against enoyl acyl carrier protein reductase (InhA) enzyme of M. tuberculosis. © 2015 Published by Elsevier Ltd.
dc.identifier.citationBioorganic and Medicinal Chemistry Letters, 2015, 25, 23, pp. 5540-5545
dc.identifier.issn0960894X
dc.identifier.urihttps://doi.org/10.1016/j.bmcl.2015.10.057
dc.identifier.urihttps://idr.nitk.ac.in/handle/123456789/26183
dc.publisherElsevier Ltd
dc.subjectacyl carrier protein
dc.subjectenoyl acyl carrier protein reductase (NADH)
dc.subjectethambutol
dc.subjectisoniazid
dc.subjectoxidoreductase
dc.subjectpyrazole
dc.subjectpyrazole derivative
dc.subjecttuberculostatic agent
dc.subjectantiinfective agent
dc.subjectanimal cell
dc.subjectantibacterial activity
dc.subjectArticle
dc.subjectbacterial strain
dc.subjectcomputer model
dc.subjectcontrolled study
dc.subjectdrug design
dc.subjectdrug synthesis
dc.subjectin vitro study
dc.subjectminimum inhibitory concentration
dc.subjectmolecular docking
dc.subjectMycobacterium tuberculosis
dc.subjectnonhuman
dc.subjectstructure activity relation
dc.subjectVero cell line
dc.subjectbacterium
dc.subjectbinding site
dc.subjectchemical structure
dc.subjectchemistry
dc.subjectdrug effects
dc.subjectIC50
dc.subjectmicrobial sensitivity test
dc.subjectmolecular model
dc.subjectsynthesis
dc.subjectAnti-Bacterial Agents
dc.subjectAntitubercular Agents
dc.subjectBacteria
dc.subjectBinding Sites
dc.subjectDrug Design
dc.subjectInhibitory Concentration 50
dc.subjectIsoniazid
dc.subjectMicrobial Sensitivity Tests
dc.subjectModels, Molecular
dc.subjectMolecular Docking Simulation
dc.subjectMolecular Structure
dc.subjectPyrazoles
dc.titleNew INH-pyrazole analogs: Design, synthesis and evaluation of antitubercular and antibacterial activity

Files

Collections